Stanford researchers have developed antisense oligonucleotides (ASOs) that selectively block pathological cryptic exon inclusions in key neuronal genes to treat TDP-43-related neurodegenerative diseases.
While conventionally known for its function as an inhibitory neurotransmitter, GABA signaling was recently discovered to have a significant role in fate determination of blood stem cells.
Researchers at Stanford have developed a new method for using bacterial lipoproteins as nanocarriers for small molecule drugs, opening the door to a novel class of biodegradable, protein-based drug delivery vehicles.
KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity.
Researchers from Stanford University and the Technical University of Munich (TUM) propose a new approach for treating Type 2 Diabetes (T2D) by targeting the cathelicidin gene expression pathway.
Huntington's Disease and other ataxias are devastating diseases without any cure or treatment. They are caused by the formation of toxic oligomeric and the aggregation of the Huntintin (HTT) protein.
Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Researchers at Stanford have developed an IL-7–conjugated lipid nanoparticle (LNP) platform designed to substantially improve mRNA delivery to T cells for direct in vivo T-cell engineering.
Stanford researchers have developed a next-generation programmable transcriptional activation platform, TIGRa, that addresses key limitations of CRISPRa technologies, including large size, limited multiplexing capacity, and delivery constraints.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Stanford researchers have developed Microbe-Independent Deep Assembly and Screening (MIDAS-M), a novel platform that dramatically accelerates the cloning of protein variants and its analysis in mammalian cells.
Imaging methods that can visualize biological samples with high and temporal resolution are critical for modern biomedical research and clinical practice.
Stanford researchers have developed a personalized arrhythmia risk prediction tool for dilated cardiomyopathy (DCM) patients using patient-derived induced pluripotent stem cells (iPSCs) to replicate heart biology and accurately predict arrhythmia risk, enabling timely interven
Researchers in Prof. Mark Schnitzer's laboratory have developed a robotic optical microscopy system which enables users to simultaneously view and record separate areas of a single three-dimensional sample.